STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES

FOURTH QUARTER 2014 (OCT - DEC)

 • Net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding
to an increase of 28 percent.
• Operating income before depreciation and amortization (EBITDA) excluding one
-time expenses amounted to SEK 5.9 (3.0) million, corresponding to an EBITDA
margin of 23 percent. One-time expenses of SEK 2.8 million related to the
dispute regarding three Vivoline patents/patent applications have been charged
against the quarter.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK
3.1 (3.0) million, corresponding to an EBITDA margin of 12 percent.
• Net income amounted to SEK -0.3 (2.4) million, resulting in earnings per share
of SEK -0.01 (0.12).
• Cash flow from operating activities was SEK -5.4 (7.1) million due to
increased working capital effecting cash flow by -7.8 SEK million.
• Net sales for consumables in the quarter amounted to SEK 25.5 (20.0) million,
corresponding to an increase of 28 percent in SEK. Sales for consumables
increased by 17 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 34 (21) percent of the total sales of consumables.
• Two XPS™ contracts were signed during the quarter.
• XVIVO has received Vinnova financing for cancer research in Europe.
• The Arbitration Board ruled that XVIVO does not have agreement rights to three
Vivoline patents/patent applications, pursuant to the improvement clause in the
current agreement that the company has with Igelösa. The company’s own products,
STEEN Solution™, which is protected by patents that are valid until 2021, and
Perfadex® are not part of the dispute.

THE PERIOD 2014 (JAN – DEC)

 • Net sales in the period amounted to SEK 84.7 (68.9) million, corresponding to
an increase of 23 percent.
• Operating income before depreciation and amortization (EBITDA) excluding one
-time expenses amounted to SEK 15.7 (13.0) million, corresponding to an EBITDA
margin of 19 percent. One-time expenses of SEK 4.3 million related to the
dispute regarding three Vivoline patents/patent applications have been charged
against the period.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK
11.4 (13.0) million, corresponding to an EBITDA margin of 13 percent.
• Net income amounted to SEK 3.7 (8.1) million, resulting in earnings per share
of SEK 0.18 (0.41).
• Cash flow from operating activities was SEK -3.7 (13.5) million and was
affected by increased working capital of -10.5 SEK million and paid taxes of SEK
-4.6 million.
• Net sales for consumables in the period amounted to SEK 83.2 (68.9) million,
corresponding to an increase of 21 percent in SEK. Sales for consumables
increased by 15 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 27 (16) percent of the total sales of consumables.
• XPS™ (Xvivo Perfusion System) received a CE mark, allowing XPS™ and the
accompanying single-use products to be sold in Europe.
• The FDA granted marketing approval for XPS™ and STEEN Solution™, allowing
STEEN Solution™, XPS™ and the accompanying single-use products to be sold in the
US.
• XVIVO Perfusion completed a share issue through a private placement of SEK 73
million.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

 • Two XPS™ contracts were signed after the end of the quarter in addition to
the twp contracts signed during quarter four.

CONFERENCE CALL

 CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET
on Thursday, February 5, 2015. Telephone: +44 (0) 1452 555566, enter code
56175829.

February 5, 2015
Gothenburg

XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on February 5, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com